Zymofix secures €2 million to scale microbial solutions for sustainable agriculture and beyond

• Additional financing to advance proprietary fermentation technology • Looking to expand the team to support its rapid growth • Rebranded from N-Fix to Zymofix – learn more at Zymofix.com

November 12, 2024

Protealis Secures 1.2m EUR VLAIO grants to Advance Local High-Performing Legume Crop Innovations in Northern Europe

November 6, 2024

Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety

October 1, 2024

Tanai Therapeutics secures additional financing from Novo Nordisk and BioGeneration Ventures for novel obesity drug

September 19, 2024

European Soy Industry Gathered in Ghent, Belgium during most Northern Soy Field Event

Protealis Hosted First Soy Field Day Event in Belgium to Highlight Innovations in Northern European Soy Cultivation

September 12, 2024

MRM Health, a VIB spin-off company, appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors

Ghent, Belgium, September 10, 2024 – MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to the newly created role of Chief Business Officer. Concurrently, the company has strengthened its Board of Directors with the appointment of industry veteran Ron Robison, M.D.

September 10, 2024

Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

July 26, 2024

Protealis, a VIB spin-off company, appoints Frank van Lierde to its Board of Directors

Having extensive experience in the food and bio-industrial sectors, Frank van Lierde brings invaluable expertise to Protealis as the company expands its commercial footprint with innovative high yield, high protein soy varieties adopted to Northern Europe.

July 2, 2024

Augustine Therapeutics, a VIB spin-off company, raises EUR 17 million in a first closing of series A

Proceeds used to advance Augustine's lead candidate into Phase 1/2 clinical trial in neurological diseases

June 26, 2024